Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCP-rCpa5
- Development stage
- Preclinical
- Lead developer
- The University of Texas at San Antonio
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
GCP-rCpa5 is a preclinical recombinant protein subunit vaccine candidate being developed for the prevention of Valley Fever (coccidioidomycosis), a potentially fatal respiratory fungal disease caused by *Coccidioides* species (*Coccidioides immitis* and *Coccidioides posadasii*). The vaccine consists of the engineered recombinant *Coccidioides* polypeptide antigen 5 (rCpa5), which contains multiple T-cell epitopes for prevalent human MHC-II alleles (such as HLA-DR4 and HLA-DR3) to enhance solubility and broaden HLA coverage compared to its predecessor rCpa1. The rCpa5 antigen is formulated with glucan-chitin particles (GCPs) as an adjuvant and delivery system. GCP-rCpa5 stimulates protective Th1 and Th17 immune responses and has demonstrated efficacy in reducing fungal burden and improving survival in animal models of *Coccidioides* infection.
- Other names
- glucan-chitin particle-formulated rCpa5glucan-chitin particle-formulated recombinant Coccidioides polypeptide antigen 5rCpa5 vaccinerCpa-5 vaccinerCpa 5 vaccine
02
Targets
CARD9 (Caspase recruitment domain-containing protein 9)CLEC6A (C-type lectin domain family 6 member A)CPA5 (Carboxypeptidase A5)CLEC7A (Dectin-1)
Beyond the preview
Go deeper on GCP-rCpa5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCP-rCpa5.